Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganetespib - Aldeyra Therapeutics

Next Previous
Drug Profile

Ganetespib - Aldeyra Therapeutics

Alternative Names: ADX 1612; SARC 023; STA-9090

Latest Information Update: 01 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Aldeyra Therapeutics; Cancer Research UK; Cardiff University; Emory University; Innsbruck Medical University; Madrigal Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; Synta Pharmaceuticals
  • Class Antineoplastics; Antivirals; Eye disorder therapies; Indoles; Resorcinols; Small molecules; Triazoles
  • Mechanism of Action HSP90 heat-shock protein inhibitors; Nucleic acid inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Malignant-mesothelioma; Ovarian cancer
  • Suspended Lymphoproliferative disorders
  • Discontinued Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; COVID 2019 infections; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Rectal cancer; Sarcoma; Small cell lung cancer; Uveal melanoma

Most Recent Events

  • 13 Sep 2024 Efficacy and adverse events data from a phase II tril in Ovarian cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 01 Sep 2023 Katholieke Universiteit Leuven completes the phase II trial for Ovarian cancer (Combination therapy, Second line therapy or greater) in Belgium, France, Italy, Germany, Austria (NCT03783949)
  • 29 Sep 2022 Discontinued - Phase-II for COVID-2019 infections (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top